Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$7.41 ▲ +0.17
(+2.35%)
MKT CAP: $489.2M • VOL: 1.04M
52W L $5 52W H $16
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$6
MEDIAN
$8
MEAN
$8
HIGH
$10
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE RGNX TAPE
RGNX // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $8.97 | $8.52 | 2025-02-14 | $6.74 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $9.34 | $8.74 | 2025-02-06 | $6.97 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $8.45 | $8.15 | 2025-01-29 | $7.11 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $7.56 | — | 2025-01-17 | $7.26 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $6.52 | $7.04 | 2025-01-09 | $6.59 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $8.82 | $7.71 | 2024-12-18 | $6.45 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $7.19 | $7.48 | 2024-12-04 | $6.89 | -4.3% | 48% | C |